Status:
RECRUITING
OP2C : Prialt® Observatory in Clinical Practice
Lead Sponsor:
Institut Cancerologie de l'Ouest
Collaborating Sponsors:
Esteve
Conditions:
Refractory Pain
Eligibility:
All Genders
18+ years
Brief Summary
Ziconotide is a strong analgesic marketed since 2005 in Europe and reserved for the intrathecal route. Its efficacy has been proven in particular by 3 randomized clinical studies. It is particularly ...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Severe refractory chronic pain requiring intrathecal analgesia
- Candidate for intrathecal analgesia treatment with ziconotide
- Patient informed about the study and agreeing to take part in.
Exclusion
- Contraindications to ziconotide
Key Trial Info
Start Date :
July 10 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04321408
Start Date
July 10 2020
End Date
September 1 2027
Last Update
August 17 2025
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut de Cancerologie de L'Ouest
Angers, France, 49000
2
Centre Hospitalier Departemental La Roche Sur Yon
La Roche-sur-Yon, France, 85000
3
Centre Leon Berard
Lyon, France, 69008
4
Institut de Cancerologie de Montpellier
Montpellier, France, 34298